Physician profile
Philip Edward Lammers
NPI 1780802330
$158,900.59
in general payments reported to CMS, 2019-2025
76 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,563 · 2020: $5,330 · 2021: $5,379 · 2022: $18K · 2023: $9,636 · 2024: $49K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $40K · Food and Beverage: $10K · Travel and Lodging: $4,776 · Education: $25.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,793.25 |
| Consulting Fee | $39,843.84 |
| Food and Beverage | $10,310.19 |
| Travel and Lodging | $4,775.91 |
| Education | $25.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $87,683.22 | 2019-2025 | Datroway, Imfinzi, Enhertu |
| Amgen INC. | $17,309.90 | 2019-2025 | Imdelltra (Amg757), Imdelltra (Amg 757), Vectibix |
| Daiichi Sankyo INC. | $15,164.06 | 2019-2025 | Datroway, Enhertu, Injectafer |
| Genzyme Corporation | $12,434.15 | 2019-2024 | |
| Stemline Therapeutics INC. | $6,312.78 | 2022-2025 | Orserdu |
| Astrazeneca Uk Limited | $4,110.00 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,603.12 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Pfizer INC. | $2,153.91 | 2019-2025 | |
| Bristol Myers Squibb Company | $1,950.00 | 2023 | |
| Merck Sharp & Dohme LLC | $890.03 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $703.81 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $660.74 | 2022-2025 | |
| Eisai INC. | $636.18 | 2019-2025 | |
| Celgene Corporation | $431.56 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $420.08 | 2020-2025 | Darzalex, Talvey, Erleada |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $418.54 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Puma Biotechnology, INC. | $415.17 | 2019-2025 | |
| Genentech USA, INC. | $350.40 | 2019-2025 | Perjeta, Phesgo, Tecentriq |
| Glaxosmithkline, LLC. | $331.21 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Seagen INC. | $303.68 | 2019-2023 | Tivdak, Tukysa |
| Tempus Ai, INC | $288.46 | 2024-2025 | Xt Cdx |
| G1 Therapeutics, INC. | $254.67 | 2022-2023 | Cosela |
| Abbvie INC. | $199.14 | 2019-2025 | |
| Emd Serono, INC. | $198.27 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $169.74 | 2022-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $163.41 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $158.57 | 2022-2024 | Rezlidhia, Tavalisse |
| Exelixis INC. | $146.71 | 2019-2025 | Cabometyx |
| Incyte Corporation | $142.23 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Beigene USA, INC. | $124.46 | 2022-2024 | Brukinsa |
| Array Biopharma INC | $103.73 | 2025 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $98.93 | 2023-2024 | Zoladex, Xermelo |
| Jazz Pharmaceuticals INC. | $96.01 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.09 | 2019-2025 | Ninlaro |
| Sun Pharmaceutical Industries INC. | $88.39 | 2022-2025 | Yonsa, Odomzo |
| Deciphera Pharmaceuticals INC. | $85.19 | 2022-2023 | Qinlock |
| Taiho Oncology, INC. | $78.75 | 2023-2025 | |
| Mirati Therapeutics, INC. | $73.15 | 2023-2024 | Krazati |
| Iovance Biotherapeutics, INC. | $73.13 | 2025 | Amtagvi |
| Sobi, INC | $71.16 | 2024-2025 | |
| Genmab U.S., INC. | $66.44 | 2023-2025 | Epkinly |
| Springworks Therapeutics, INC. | $61.94 | 2024-2025 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $58.93 | 2022-2025 | Fotivda |
| Servier Pharmaceuticals LLC | $53.10 | 2023 | |
| Coherus Oncology, INC. | $51.30 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.61 | 2024-2025 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $38.41 | 2020-2024 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $37.18 | 2025 | |
| Pharmaessentia USA Corporation | $34.83 | 2023-2024 | Besremi |
| Karyopharm Therapeutics INC. | $34.77 | 2024-2025 | Xpovio |
| Clovis Oncology, INC. | $32.97 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $32.02 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.10 | 2023 | Libtayo |
| Sumitomo Pharma America, INC. | $29.14 | 2023 | Orgovyx |
| Beone Medicines USA, INC. | $26.01 | 2025 | Brukinsa |
| Teva Pharmaceuticals USA, INC. | $25.72 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.85 | 2019 | |
| Secura Bio, INC. | $24.34 | 2022 | |
| Recordati_rare_diseases_inc. | $23.88 | 2025 | Enjaymo |
| Astellas Pharma US INC | $20.48 | 2023 | Xospata |
| Geron Corporation | $19.43 | 2025 | Rytelo |
| Kite Pharma, INC. | $17.34 | 2023 | |
| Adc Therapeutics America, INC. | $17.13 | 2024 | |
| Legend Biotech USA INC. | $16.87 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $16.25 | 2023 | Empaveli |
| Morphosys, US INC. | $15.47 | 2023 | Monjuvi |
| Boston Scientific Corporation | $14.89 | 2019 | |
| Genentech, INC. | $14.23 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.13 | 2024 | Xarelto |
| Cti Biopharma Corp. | $13.10 | 2023 | Vonjo |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,710.64 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Lammers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.